BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 17986289)

  • 21. Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study.
    Schumacher MC; Holmäng S; Davidsson T; Friedrich B; Pedersen J; Wiklund NP
    Eur Urol; 2010 Feb; 57(2):293-9. PubMed ID: 19913351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy.
    Margel D; Tal R; Golan S; Kedar D; Engelstein D; Baniel J
    Urology; 2007 Jan; 69(1):78-82. PubMed ID: 17270621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome of very large superficial bladder tumours: a 10-year experience.
    Gupta SK; Parr NJ
    Scand J Urol Nephrol; 2008; 42(3):243-8. PubMed ID: 18432531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
    Iida S; Kondo T; Kobayashi H; Hashimoto Y; Goya N; Tanabe K
    Int J Urol; 2009 Mar; 16(3):287-92. PubMed ID: 19207115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors.
    Filbeck T; Pichlmeier U; Knuechel R; Wieland WF; Roessler W
    J Urol; 2002 Jul; 168(1):67-71. PubMed ID: 12050494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Value of the photodynamic method in the diagnosis of superficial bladder tumors].
    Lipiński MI; Jeromin LM
    Wiad Lek; 2004; 57 Suppl 1():192-5. PubMed ID: 15884237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis.
    Burger M; Zaak D; Stief CG; Filbeck T; Wieland WF; Roessler W; Denzinger S
    Eur Urol; 2007 Jul; 52(1):142-7. PubMed ID: 17267099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The treated natural history of high risk superficial bladder cancer: 15-year outcome.
    Cookson MS; Herr HW; Zhang ZF; Soloway S; Sogani PC; Fair WR
    J Urol; 1997 Jul; 158(1):62-7. PubMed ID: 9186324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Results of BCG in the treatment of pTa and pT1 bladder tumors. Evaluation of a long protocol using 75 mg of Pasteur strain BCG].
    Ayed M; Ben Hassine L; Ben Slama R; Chelbi N; Ghozzi S; Drissi H; Jemni M; Chebil M
    Prog Urol; 1998 Apr; 8(2):206-10. PubMed ID: 9615929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
    Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
    BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?
    Weiss C; Wolze C; Engehausen DG; Ott OJ; Krause FS; Schrott KM; Dunst J; Sauer R; Rödel C
    J Clin Oncol; 2006 May; 24(15):2318-24. PubMed ID: 16710030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin.
    Gee JR; Jarrard DF; Bruskewitz RC; Moon TD; Hedican SP; Leverson GE; Nakada SY; Messing EM
    BJU Int; 2009 Mar; 103(6):736-9. PubMed ID: 19007364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy.
    Lambert EH; Pierorazio PM; Olsson CA; Benson MC; McKiernan JM; Poon S
    BJU Int; 2007 Jul; 100(1):33-6. PubMed ID: 17552951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer.
    Chen CH; Shun CT; Huang KH; Huang CY; Tsai YC; Yu HJ; Pu YS
    BJU Int; 2007 Aug; 100(2):281-6; discussion 286. PubMed ID: 17419696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
    Järvinen R; Kaasinen E; Sankila A; Rintala E;
    Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer.
    Gårdmark T; Jahnson S; Wahlquist R; Wijkström H; Malmström PU
    BJU Int; 2007 Apr; 99(4):817-20. PubMed ID: 17244282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.